AK112
Phase 3Small molecule
AK112 is one of 311 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
11
Indications
40
Total Trials
31
Active Trials
310
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1AK112
SSummit Therapeutics
Phase 3
Yervoy
Bristol-Myers SquibbPreclinical
PORTRAZZA
Eli LillyPreclinical
Lenvima
EisaiPreclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
REGN2810
RegeneronPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Show 1 more trial
Hepatocellular Carcinoma3 trials
Metastatic Colorectal Cancer3 trials
Ovarian Cancer3 trials
19 more indications
Pancreatic Cancer2 trials
Chemotherapy2 trials
Bispecific Antibody2 trials
Triple-Negative Breast Cancer2 trials
Advanced Solid Tumors2 trials
Advanced Malignant Tumors2 trials
First-line Treatment1 trial
Biliary Tract Cancer1 trial
Leptomeningeal Metastasis1 trial
Phase II Clinical Study1 trial
Neoadjuvant Therapy1 trial
Lung Cancer1 trial
Head and Neck Squamous Cell Carcinoma1 trial
AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06537011·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AK112. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSummit Therapeutics